My Top 3 Biotech Stocks for May 2026

Schrödinger reported $256 million in 2025 revenue, including $200 million from software, and management guided 10% to 15% ACV growth in 2026 to $218 million-$228 million, highlighting a rare revenue-generating AI biotech platform. Sarepta delivered $1.86 billion in 2025 net product revenue, with Elevidys contributing about $899 million, but ongoing FDA scrutiny and safety concerns remain a major overhang. NRX Pharmaceuticals has two near-term catalysts: a potential FDA decision this summer and FDA clearance for a depression trial, though it remains highly speculative and financing risk is elevated.

Analysis

The cleanest second-order read is that this is less a pure biotech call than a quality-screening event inside a still-scarce capital market. The market is rewarding companies that can self-fund longer development arcs: SDGR’s software annuity lowers dilution risk and should support a re-rating versus pre-revenue AI-biotech peers, while SRPT’s cash generation makes it more resilient than typical regulatory-risk names. That said, SRPT’s revenue base may actually make the stock more volatile near headlines because any fresh safety issue can compress multiple years of embedded franchise value in days.

The underappreciated dynamic is that the current backdrop favors platform businesses and penalizes binary single-asset stories unless catalysts are near-dated. SDGR’s real optionality is not the software business itself but whether that business keeps the company out of the financing penalty box long enough for pipeline readouts to matter; that creates a longer-duration call option with lower dilution drag than most biotech names. For NRXPW, the setup is the opposite: the path to institutional attention is narrow, and any delay, adverse interpretation, or capital need could overwhelm even a good FDA outcome because microcap biotech rerates are often constrained by balance-sheet credibility, not just clinical data.

Consensus may be underestimating how much of this is about investor positioning rather than fundamentals. SRPT already has a crowded short-interest / headline-risk profile, so a modestly better safety tone or regulatory clarification could trigger a sharp tactical squeeze, but if the market concludes the company cannot de-risk the label, downside can remain persistent despite sales. The bigger missed point is that stronger biotech cash flows from names like SRPT can divert capital away from earlier-stage developers, making the market more selective and raising the bar for NRXPW-type stories to get sustained sponsorship.

Key Decisions for Investors

• Long SDGR vs. basket short of pre-revenue AI-biotech peers for 3-6 months: own the self-funding platform and short the dilution-risk cohort; target modest multiple expansion with lower drawdown risk.
• Buy SRPT only as a tactical event-driven long, ideally via call spreads over the next 1-2 quarters: upside can be sharp on regulatory relief, but size small because a renewed safety headline can erase gains quickly.
• Avoid outright long NRXPW until a binary FDA decision is in hand; if trading it, use call spreads or a small starter position into the catalyst window so upside is financed by limited premium at risk.
• Pair trade: long SDGR / short a high-burn, no-revenue biotech ETF constituent basket over 6 months; thesis is that capital markets will continue to reward revenue-backed platforms and punish serial diluters.
• If SRPT rallies on a benign FDA outcome, fade part of the move into strength rather than chase: near-term squeeze potential is real, but the post-event multiple is vulnerable if the market still assigns a lasting safety discount.